Clinical Cancer Research Joint Metastasis Research Society-AACR Conference on Metastasis Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, M. H.
Right arrow Articles by Pazdur, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, M. H.
Right arrow Articles by Pazdur, R.
Clinical Cancer Research Vol. 10, 1212-1218, February 2004
© 2004 American Association for Cancer Research

Report from the FDA

United States Food and Drug Administration Drug Approval Summary

Gefitinib (ZD1839; Iressa) Tablets

Martin H. Cohen, Grant A. Williams, Rajeshwari Sridhara, Gang Chen, W. David McGuinn, Jr., David Morse, Sophia Abraham, Atiqur Rahman, Chenyi Liang, Richard Lostritto, Amy Baird and Richard Pazdur

Division of Oncology Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland

ABSTRACT

On May 5, 2003, gefitinib (Iressa; ZD1839) 250-mg tablets (AstraZeneca Inc.) received accelerated approval by the United States Food and Drug Administration as monotherapy for patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies. Information provided in this summary includes chemistry manufacturing and controls, clinical pharmacology, and clinical trial efficacy and safety results. Gefitinib is an anilinoquinazoline compound with the chemical name 4-quinazolinamine,N-(3-chloro-4-flurophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]. It has the molecular formula C22H24ClFN4O3. Gefitinib is often referred to as a "specific" or "selective" inhibitor of epidermal growth factor receptor. Studies demonstrate, however, that gefitinib inhibits the activity of other intracellular transmembrane tyrosine-specific protein kinases at concentrations similar to those at which it inhibits the epidermal growth factor signal. Maximum plasma concentrations resulting from clinically relevant doses are 0.5–1 µM or more, well within the IC50 values of several tyrosine kinases. No clinical studies have been performed that demonstrate a correlation between epidermal growth factor receptor expression and response to gefitinib. Gefitinib is 60% available after oral administration and is widely distributed throughout the body. Gefitinib is extensively metabolized in the liver by cytochrome P450 3A4 enzyme. Over a 10-day period, approximately 86% of an orally administered radioactive dose is recovered in the feces, with <4% of the dose in the urine. After daily oral administration, steady-state plasma levels are reached in 10 days and are 2-fold higher than those achieved after single doses. Gefitinib effectiveness was demonstrated in a randomized, double-blind, Phase II, multicenter trial comparing two oral doses of gefitinib (250 versus 500 mg/day). A total of 216 patients were enrolled. The 142 patients who were refractory to or intolerant of a platinum and docetaxel comprised the evaluable population for the efficacy analysis. A partial tumor response occurred in 14% (9 of 66) of patients receiving 250 mg/day gefitinib and in 8% (6 of 76) of patients receiving 500 mg/day gefitinib. The overall objective response rate (RR) for both doses combined was 10.6% (15 of 142 patients; 95% confidence interval, 6.0–16.8%). Responses were more frequent in females and in nonsmokers. The median duration of response was 7.0 months (range, 4.6–18.6+ months). Other submitted data included the results of two large trials conducted in chemotherapy-naive, stage III and IV non-small cell lung cancer patients. Patients were randomized to receive gefitinib (250 or 500 mg daily) or placebo, in combination with either gemcitabine plus cisplatin (n = 1093) or carboplatin plus paclitaxel (n = 1037). Results from this study showed no benefit (RR, time to progression, or survival) from adding gefitinib to chemotherapy. Consequently, gefinitib is only recommended for use as monotherapy. Common adverse events associated with gefitinib treatment included diarrhea, rash, acne, dry skin, nausea, and vomiting. Interstitial lung disease has been observed in patients receiving gefitinib. Worldwide, the incidence of interstitial lung disease was about 1% (2% in the Japanese post-marketing experience and about 0.3% in a United States expanded access program). Approximately one-third of the cases have been fatal. Gefitinib was approved under accelerated approval regulations on the basis of a surrogate end point, RR. No controlled gefitinib trials, to date, demonstrate a clinical benefit, such as improvement in disease-related symptoms or increased survival. Accelerated approval regulations require the sponsor to conduct additional studies to verify that gefitinib therapy produces such benefit.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. Hoshi, H. Takakura, Y. Mitani, K. Tatsumi, N. Momiyama, Y. Ichikawa, S. Togo, T. Miyagi, Y. Kawai, Y. Kogo, et al.
Rapid Detection of Epidermal Growth Factor Receptor Mutations in Lung Cancer by the SMart-Amplification Process
Clin. Cancer Res., September 1, 2007; 13(17): 4974 - 4983.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. Sekine, M. Sumi, Y. Ito, T. Kato, Y. Fujisaka, H. Nokihara, N. Yamamoto, H. Kunitoh, Y. Ohe, and T. Tamura
Phase I Study of Cisplatin Analogue Nedaplatin, Paclitaxel, and Thoracic Radiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Jpn. J. Clin. Oncol., April 23, 2007; (2007) hym008v1.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Araujo, R. Ribeiro, I. Azevedo, A. Coelho, M. Soares, B. Sousa, D. Pinto, C. Lopes, R. Medeiros, and G. V. Scagliotti
Genetic Polymorphisms of the Epidermal Growth Factor and Related Receptor in Non-Small Cell Lung Cancer--A Review of the Literature
Oncologist, February 1, 2007; 12(2): 201 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Rosell, M. Taron, N. Reguart, D. Isla, and T. Moran
Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway
Clin. Cancer Res., December 15, 2006; 12(24): 7222 - 7231.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Li, M. O. Karlsson, J. Brahmer, A. Spitz, M. Zhao, M. Hidalgo, and S. D. Baker
CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors
J Natl Cancer Inst, December 6, 2006; 98(23): 1714 - 1723.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
Y. Yan, Y. Lu, M. Wang, H. Vikis, R. Yao, Y. Wang, R. A. Lubet, and M. You
Effect of an Epidermal Growth Factor Receptor Inhibitor in Mouse Models of Lung Cancer
Mol. Cancer Res., December 1, 2006; 4(12): 971 - 981.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Y. Sato, K. Harada, S. Furubo, K. Kizawa, T. Sanzen, M. Yasoshima, S. Ozaki, K. Isse, M. Sasaki, and Y. Nakanuma
Inhibition of Intrahepatic Bile Duct Dilation of the Polycystic Kidney Rat with a Novel Tyrosine Kinase Inhibitor Gefitinib
Am. J. Pathol., October 1, 2006; 169(4): 1238 - 1250.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Alvarado, T. A. Evans, R. Sharma, M. A. Lemmon, and J. B. Duffy
Argos Mutants Define an Affinity Threshold for Spitz Inhibition in Vivo
J. Biol. Chem., September 29, 2006; 281(39): 28993 - 29001.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. A. Zell, S.-H. I. Ou, A. Ziogas, and H. Anton-Culver
Long-term survival differences for bronchiolo-alveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosis
Ann. Onc., August 1, 2006; 17(8): 1255 - 1262.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. H. Johnson
Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
Clin. Cancer Res., July 15, 2006; 12(14): 4451s - 4457s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Ando, I. Okamoto, N. Yamamoto, K. Takeda, K. Tamura, T. Seto, Y. Ariyoshi, and M. Fukuoka
Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib
J. Clin. Oncol., June 1, 2006; 24(16): 2549 - 2556.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Van Schaeybroeck, J. Kyula, D. M. Kelly, A. Karaiskou-McCaul, S. A. Stokesberry, E. Van Cutsem, D. B. Longley, and P. G. Johnston
Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells
Mol. Cancer Ther., May 1, 2006; 5(5): 1154 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Zell, S.-H. I. Ou, A. Ziogas, and H. Anton-Culver
In Reply:
J. Clin. Oncol., April 20, 2006; 24(12): 1963 - 1964.
[Full Text] [PDF]

Home page
 Neuro OncolHome page
S. Shimato, T. Mitsudomi, T. Kosaka, Y. Yatabe, T. Wakabayashi, M. Mizuno, N. Nakahara, H. Hatano, A. Natsume, D. Ishii, et al.
EGFR mutations in patients with brain metastases from lung cancer: Association with the efficacy of gefitinib
Neuro-oncol, April 1, 2006; 8(2): 137 - 144.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Angelucci, G. L. Gravina, N. Rucci, D. Millimaggi, C. Festuccia, P. Muzi, A. Teti, C. Vicentini, and M. Bologna
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 197 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Bruzzese, E. Di Gennaro, A. Avallone, S. Pepe, C. Arra, M. Caraglia, P. Tagliaferri, and A. Budillon
Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN-{alpha} in Head and Neck Cancer Cells In vitro and In vivo
Clin. Cancer Res., January 15, 2006; 12(2): 617 - 625.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K.-i. Fujita, Y. Ando, M. Narabayashi, T. Miya, F. Nagashima, W. Yamamoto, K. Kodama, K. Araki, H. Endo, and Y. Sasaki
GEFITINIB (IRESSA) INHIBITS THE CYP3A4-MEDIATED FORMATION OF 7-ETHYL-10-(4-AMINO-1-PIPERIDINO)CARBONYLOXYCAMPTOTHECIN BUT ACTIVATES THAT OF 7-ETHYL-10-[4-N-(5-AMINOPENTANOIC ACID)-1-PIPERIDINO]CARBONYLOXYCAMPTOTHECIN FROM IRINOTECAN
Drug Metab. Dispos., December 1, 2005; 33(12): 1785 - 1790.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Albitar, L. L. Laidler, R. Abdallah, and K. K. Leslie
Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors
Mol. Cancer Ther., December 1, 2005; 4(12): 1891 - 1899.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
R. F. Munden, S. S. Swisher, C. W. Stevens, and D. J. Stewart
Imaging of the Patient with Non-Small Cell Lung Cancer
Radiology, December 1, 2005; 237(3): 803 - 818.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Zell, S.-H. I. Ou, A. Ziogas, and H. Anton-Culver
Epidemiology of Bronchioloalveolar Carcinoma: Improvement in Survival After Release of the 1999 WHO Classification of Lung Tumors
J. Clin. Oncol., November 20, 2005; 23(33): 8396 - 8405.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. H. Garfield
Modern Treatment of Lung Cancer: CASE 2. Response to Erlotinib After Failure of Gefitinib in a Patient With Advanced Non-Small-Cell Lung Carcinoma
J. Clin. Oncol., October 20, 2005; 23(30): 7738 - 7740.
[Full Text] [PDF]

Home page
 BloodHome page
K. Stegmaier, S. M. Corsello, K. N. Ross, J. S. Wong, D. J. DeAngelo, and T. R. Golub
Gefitinib induces myeloid differentiation of acute myeloid leukemia
Blood, October 15, 2005; 106(8): 2841 - 2848.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
A. Onn, D. H. Choe, R. S. Herbst, A. M. Correa, R. F. Munden, M. T. Truong, A. A. Vaporciyan, T. Isobe, M. Z. Gilcrease, and E. M. Marom
Tumor Cavitation in Stage I Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome
Radiology, October 1, 2005; 237(1): 342 - 347.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. C. Daw, W. L. Furman, C. F. Stewart, L. C. Iacono, M. Krailo, M. L. Bernstein, J. E. Dancey, R. A. Speights, S. M. Blaney, J. M. Croop, et al.
Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children's Oncology Group Study
J. Clin. Oncol., September 1, 2005; 23(25): 6172 - 6180.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Onoda, H. Mitsufuji, N. Yanase, S. Ryuge, E. Kato, M. Wada, K. Ishii, S. Hagiri, M. Yamamoto, M. Yokoba, et al.
Drug Interaction Between Gefitinib and Warfarin
Jpn. J. Clin. Oncol., August 1, 2005; 35(8): 478 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Schilder, M. W. Sill, X. Chen, K. M. Darcy, S. L. Decesare, G. Lewandowski, R. B. Lee, C. A. Arciero, H. Wu, and A. K. Godwin
Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study
Clin. Cancer Res., August 1, 2005; 11(15): 5539 - 5548.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. L. Mu, L. Y. Li, X. T. Zhang, M. Z. Wang, R. E. Feng, Q. C. Cui, H. S. Zhou, and B. Q. Guo
Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non-Small Cell Lung Cancer
Clin. Cancer Res., June 15, 2005; 11(12): 4289 - 4294.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Nemunaitis, I. Eiseman, C. Cunningham, N. Senzer, A. Williams, P. F. Lenehan, S. C. Olson, P. Bycott, M. Schlicht, R. Zentgraff, et al.
Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer
Clin. Cancer Res., May 15, 2005; 11(10): 3846 - 3853.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Giaccone
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-Small-Cell Lung Cancer
J. Clin. Oncol., May 10, 2005; 23(14): 3235 - 3242.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. P. Lim
Mining the Tumor Phosphoproteome for Cancer Markers
Clin. Cancer Res., May 1, 2005; 11(9): 3163 - 3169.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Perez-Soler, J. P. Delord, A. Halpern, K. Kelly, J. Krueger, B. M. Sureda, J. von Pawel, J. Temel, S. Siena, D. Soulieres, et al.
HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum
Oncologist, May 1, 2005; 10(5): 345 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K.-S. Kim, J.-Y. Jeong, Y.-C. Kim, K.-J. Na, Y.-H. Kim, S.-J. Ahn, S.-M. Baek, C.-S. Park, C.-M. Park, Y.-I. Kim, et al.
Predictors of the Response to Gefitinib in Refractory Non-Small Cell Lung Cancer
Clin. Cancer Res., March 15, 2005; 11(6): 2244 - 2251.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Shigematsu, L. Lin, T. Takahashi, M. Nomura, M. Suzuki, I. I. Wistuba, K. M. Fong, H. Lee, S. Toyooka, N. Shimizu, et al.
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
J Natl Cancer Inst, March 2, 2005; 97(5): 339 - 346.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. B. Elkind, Z. Szentpetery, A. Apati, C. Ozvegy-Laczka, G. Varady, O. Ujhelly, K. Szabo, L. Homolya, A. Varadi, L. Buday, et al.
Multidrug Transporter ABCG2 Prevents Tumor Cell Death Induced by the Epidermal Growth Factor Receptor Inhibitor Iressa (ZD1839, Gefitinib)
Cancer Res., March 1, 2005; 65(5): 1770 - 1777.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. P. Stabile, J. S. Lyker, C. T. Gubish, W. Zhang, J. R. Grandis, and J. M. Siegfried
Combined Targeting of the Estrogen Receptor and the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects
Cancer Res., February 15, 2005; 65(4): 1459 - 1470.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Tokumo, S. Toyooka, K. Kiura, H. Shigematsu, K. Tomii, M. Aoe, K. Ichimura, T. Tsuda, M. Yano, K. Tsukuda, et al.
The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non-Small Cell Lung Cancers
Clin. Cancer Res., February 1, 2005; 11(3): 1167 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Brehmer, Z. Greff, K. Godl, S. Blencke, A. Kurtenbach, M. Weber, S. Muller, B. Klebl, M. Cotten, G. Keri, et al.
Cellular Targets of Gefitinib
Cancer Res., January 15, 2005; 65(2): 379 - 382.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. Kuribayashi, K. Kataoka, T. Kurabayashi, and M. Miura
Evidence that Basal Activity, But Not Transactivation, of the Epidermal Growth Factor Receptor Tyrosine Kinase Is Required for Insulin-like Growth Factor I-Induced Activation of Extracellular Signal-Regulated Kinase in Oral Carcinoma Cells
Endocrinology, November 1, 2004; 145(11): 4976 - 4984.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. Dagher, J. Johnson, G. Williams, P. Keegan, and R. Pazdur
Accelerated Approval of Oncology Products: A Decade of Experience
J Natl Cancer Inst, October 20, 2004; 96(20): 1500 - 1509.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. F. Stewart, M. Leggas, J. D. Schuetz, J. C. Panetta, P. J. Cheshire, J. Peterson, N. Daw, J. J. Jenkins III, R. Gilbertson, G. S. Germain, et al.
Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice
Cancer Res., October 15, 2004; 64(20): 7491 - 7499.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M. Palmer, J. Geurink, K. Hahn, and J. Kolesar
Clinical pharmacology and determinates of response to gefitinib in non-small cell lung cancer
Journal of Oncology Pharmacy Practice, September 1, 2004; 10(3): 169 - 175.
[Abstract] [PDF]

Home page
 NEJMHome page
T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, et al.
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib
N. Engl. J. Med., May 20, 2004; 350(21): 2129 - 2139.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2004 by the American Association for Cancer Research.